MLBL is an oral immunostimulating vaccine consisting of bacterial standardized lysates obtained by mechanical lysis of different strains of Gram-positive and Gram-negative bacteria that can cause acute and chronic infections of the respiratory tract. Previous studies suggested a stimulating effect of MLBL both on humoral and cellular immune responses. In the present study, the in vitro effects of MLBL on human lymphocyte effector functions and its mechanisms of action were evaluated. The results show that the most remarkable effects of MLBL on the immune system are: i) activation of the IL-2 receptor (IL-2Ra) on different lymphocyte subsets (B, CD4+ T
The mucosal surfaces represent the principal ports of entry for most exogenous agents including microrganisms. Mucosal tissues are defended by a local secretory immune system, the mucosal immune system, that may act in concert with the systemic immune system. The secretory immune system provides an integrated network linking mucosal sites and regulating trafficking of mucosally activated lymphocytes from induction to effector sites. The antigenic experience of one mucosal surface can be reflected in immune effector expression at a distant surface (1) . Based on this concept of a "common mucosal immune system" (2) (3) (4) (5) , there is currently great interest in the possibility of developing mucosal vaccines.
Oral vaccines composed by lyophilized bacterial lysates have been largely used in the past to improve the efficiency of the immune response to the predominant pathogens of the respiratory tract in subjects with recurrent bacterial infections (6) (7) (8) (9) (10) (11) (12) (13) . The efficiency of a vaccine to induce a protective immunity is determined by its ability to stimulate the generation of activated cells that can become effector cells after a new encounter with the same infective agent. This generation is mediated by the production of regulatory cytokines from immune competent cells that exert a major role in the induction and modulation of acquired immune responses (4, (14) (15) (16) .
It is well known that different patterns of cytokines are produced by different lymphocyte subsets and that cytokine production by CD4-positive (CD4+) and CD8positive (CD8+) T cells usually exhibits a Type 1 or a Type 2 phenotype (17) (18) (19) (20) (21) . Type I lymphocytes mostly produce interleukin-2 (IL2), interferon-y (IFNy) and tumor necrosis factor (TNF), are primarily involved in inflammatory cellular immunity and are essential for protection against a variety of intracellular infections. Type 2 lymphocytes produce other interleukins such as IL-4, IL-5, IL-6, IL-9, IL-1O and IL-13 and are responsible for the regulation of humoral immunity against certain extracellular infections. It is thought that the polarization towards Type I or Type 2 lymphocytes occurs at the first contact between the antigen and the immune competent cell. Effector cells are already generated after 4-5 days and their cytokine pattern is very close to the production pattern of related memory cells.
The development ofmucosal and systemic immune response depends on the nature ofantigenic stimulation and the eventual expression of Type1 versus Type 2 responses. Therefore, the study of the cytokine secretion pattern in the different subsets of immune competent cells activated by a vaccine represents an important information for evaluating its effectiveness and mechanism of action.
Bacterial extracts have been widely used as immunomodulators to prevent recurrent infections of the respiratory tract (6) (7) (8) (9) (10) (11) (12) (13) (22) (23) (24) (25) . Several preparations containing bacterial lysates are licensed for use as vaccines. MLBL is a recently developed sub-lingual immunostimulating vaccine consisting of a standardized mechanical lysate (obtained through sonication) of 8 different bacterial strains of Grampositive and Gram-negative bacteria (6 x 10 9 bacteria for each strain) selected among those most frequently implicated in acute and chronic infections of the respiratory tract (12, 13, 22) . Inactivated microorganisms or their sub-components, offer certain advantages as a potential vaccine for mucosal immunization. They are natural occurring microparticles, possess multiple antigens and are relatively inexpensive to produce. Previous studies suggested an immunopotentiating effect of MLBL on mucosal immune responses (22) . The aim of the present work was to extend our knowledge on the effects of MLBL on the immune system and to study its mechanism of action. In particular, our study evaluated the in vitro effects of MLBL on IL-2R expression both in human B lymphocytes and in CD4+ and CD8+ T lymphocytes and on cytokine production both in naive or MLBL-sensitized human lymphocytes.
MATERIALS AND METHODS

Antigens
Lyophilized bacterial lysate obtained by mechanical lysis (ISMIGEN -MLBL, lot. N. 4488) was supplied by Zambon Italia SRL, Bresso/Milan, Italy. The lysate contained 6 x 10 9 bacteria for each of the following strains:
S. aureus, S. pyogenes, S. viridans, S. pneumoniae (containing 10 9 bacteria of each of the following serotypes: TYIIEQ11, TY2/EQ22, TY3/EQI4, TY51EQ15, TY8/EQ23, TY47/EQ24), K. pneumoniae, K. ozaenae, H. injluenzae serotype B, M. catharralis. In brief, the method of preparation was the following: the bacteria were resuspended at the concentration of 1 x 10" CFU/ml. The bacterial suspension was heat-inactivated, adjusted at pH 7.0, submitted to two homogenisation cycles at 630 bar by using an APV homogenisator (model 1000, Schenker) and lyophilised.
The experiments were performed by using the lyophilisate resuspended at the concentration of 5 mg/ml in RPMI 1640-GLUTAMAX (Gibco) culture medium, sonicated for 5 minutes. Dispersal was performed overnight at 4°C under slight agitation of the bacterial suspension. Then the bacterial suspension was aliquoted and stored at -80°C until use.
PBMC separation and MLBL stimulation
Peripheral blood was obtained from healthy human donors. Mononuclearcells (PBMC) were isolatedby Ficollhypaquegradientcentrifugation. The mononuclearcells from the interface were harvested, washed and adjusted to 2 x 106/ml in RPMIl640-GLUTAMAX culture medium supplemented with 50Vlml penicillin, 50 mg/mlstreptomycin and 5% heath inactivated foetalcalf serum (PCS).
Isolated PBMC were cultured alone or incubated with 10 and 100 mg/ml ofMLBL in 6-well plates (Falcon) at 37°C in humidified 5% CO 2 for 24 h. At the end of incubation, culture supernatants and the remaining cells were removed separately and used for successive evaluations.
Cytokine determination in culture supernatants
To determine extracellular cytokine concentrations, at the end of incubation time, cell cultures were harvested, centrifuged and the cell-free supernatants were collected and stored at -80°C until assay.
Concentrations of IFNy, IL-2, IL-10 and IL-12 (p40 subunit) in the culture supernatants were measured by two-site sandwich enzyme-linked immunosorbent assay (ELISA) using commercial reagents kits (Euroclone, UK), according to the protocol of the manufacturer. Cytokine levels were expressed as ng of protein per ml.
Detection of cell surface phenotype by two color immunofluorescence staining
At the end of incubation with MLBL, the cells were harvested, washed, resuspended in phosphate buffered saline (PBS) containing 0.5% bovine serum albumin (BSA) and 0.1% sodium azide (NaN3) and were aliquoted for staining at I x 10 6 cells. To determine the cell surface phenotype for CD4, CD8 and CDI9, respectively 50 III of each of the following fluorochrome-conjugated monoclonal antibody (mAb) dilutions were used: CyChrome-conjugated mouse anti-human CD4 (PharMingen, San Diego, CA, USA), CyChromeconjugated mouse anti-human CD8 (PharMingen), PEconjugated mouse anti-human CD19 (Becton Dickinson, San Jose, CA, USA). Then, 50 III of FITC-conjugated mouse anti-human CD25 (Becton Dickinson) were added and the cells were incubated for 30 min at 4°C. As negative controls, aliquots of cell suspensions were incubated with an irrelevant isotype-matched mAb conjugated to the same fluorochrome as the sample. At the end of incubation the cells were washed twice and resuspended in PBS for flow cytometry.
Detection ofcytokine-producing cells by intracellular immunofluorescence staining
To determine the frequency of cytokine-producing CD4+ and CD8+ T lymphocytes, the method described by Di Francesco et al. (26) with minor modifications was used. In brief, 5 hrs before harvest, 2 IlM monensin (Sigma, St. Louis, MO) an inhibitor of intracellular transport, was added to block cytokine secretion in cultures (27) . At the end of incubation, cultured cells were harvested, washed, resuspended in PBS containing 0.5% bovine serum albumin (BSA) and 0.1% NaN 3 and were aliquoted for staining at 1 x 10 6 cells. Then, 50 III of FITC-conjugated mouse anti-human CD4 mAb (PharMingen), or FITC-conjugated mouse anti-human CD8 mAb (PharMingen) were added and the cells were incubated for 30 min at 4°C. At the end of the incubation, the cells were washed and fixed in 2% paraformaldehyde for 20 min, then they were washed and resuspended in PBS containing 0.5% BSA, 0.01% NaN3 and 0.1% saponin (Sigma, St. Louis, MO, USA) for permeabilization. For intracellular staining with antihuman cytokine mAbs, the following PE-labelled monoclonal antibodies, all purchased from PharMingen, were used: anti-human IL-2, anti-human IL-4, antihuman IL-I0, anti-human IFNy. As negative controls, aliquots of cell suspensions were incubated with an irrelevant isotype-matched mAb conjugated to the same fluorochrome as the sample. Finally, after the incubation at 4°C for 30 min with the above mAbs, the cells were washed twice with PBSIBSAINaN3 without saponin and resuspended in PBS/BSA for flow cytometric analysis.
Flow cytometry
A FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA) equipped with a 15 mW argon ion laser and filter setting for FITC (530 nm) and PE (585 nm) was used. Signals from light scatter channels and fluorescence-detecting photomultipliers (PMT) were collected in linear and logarithmic mode, respectively. The FL I and FL2 channels were set up and compensated on a tight lymphocyte gate using tubes with a single-labelled strongly positive antibody. Dead cells were excluded by forward and side scatter gating. Ten thousand cells were recorded for each test and signals from all parameters were captured as list mode data using CellQuest software (Becton Dickinson). List mode files were analyzed for CD25 positivity or cytokine production by FACScan Research Software (Becton Dickinson) by first defining an analysis gate on anti-CD4, anti-CD8, or anti-CD 19 positive cells. Irrelevant isotype-specific antibody was used as a control for non-specific binding of the anti-cytokine monoclonal antibodies. Statistical markers were set using the irrelevant isotype-matched controls as reference. Typically, 1% positive cells were allowed beyond the statistical markers in these controls. Previous results (28) showed that no significant cytokine immunofluorescence was present in fixed but not saponin-permeabilized cells. Data were expressed as the percentage of cells staining positive above the background staining.
Statistical analysis
Statistical significances of intergroup differences of normally distributed continuous variables was determined using Student's t test. P values of < 0.05 were considered statistically significant.
RESULTS
Effects of MLBL on cytokine concentrations in culture supernatants
Cytokine secretion was assessed by ELISA in the culture supernatants collected from the PBMC cultures treated or not with MLBL. The results ( Fig.  I) showed that the incubation for 24 hrs of PBMC with MLBL at the dose level of 100 Jlg/JlI induced the release in culture supernatants of significant amounts of all the tested cytokines, particularly IL-10 and IL-12. In control supernatants, IL-2 and IL-12 were completely absent (or their concentration was below the sensitivity limit of the test). 
Effects ofMLBL on CD25 (IL-2Ra) expression
The cells were incubated with MLBL for 24 h. At the end of this period the expression of CD25, the a chain of the IL-2 receptor, by the different cell subset was determined by two-color flow cytometry. The immunophenotypic analysis showed that incubation of PBMC with MLBL induced (Fig. 2 ) a significant increase of CD25 expression in both Band T lymphocytes. In T lymphocytes, MLBL treatment induces a statistically significant increase in the percentage of CD25+ cells in both CD4+ and CD8+ T subsets, when compared to naive cells (Fig. 2) . In CD 19+ B activated lymphocytes the frequency of cells expressing CD25 was significantly (P<O.O I) higher respect to each of the T subset. No significant changes in the proportions of both CD4+ and CD8+ T cells were observed in either naive or stimulated cells after 24 hrs of MLBL treatment (data not shown).
permeabilized cells fluorescent stained for the CD4 or CD8 surface molecules and for one of the intracytoplasmic cytokines IL-2, IL-4, IL-IO and IFNy. As shown in Fig. 3 , MLBL stimulation induced a statistically significant increase in the percentage of CD4+ T lymphocytes producing IL-2 and IL-IO, whereas no significant effect was found in the same cells concerning IFNy and IL-4 production. On the contrary (Fig. 4) , in CD8+ T lymphocytes, there was, in addition to the increasing rate ofIL-2 and IL-IOpositive cells, also an increasing rate of IFNyproducing cells. Likewise CD4+ T subset, also in CD8+ T cells the major increase was found in the percentage of IL-2-producing cells. No significant increase in the percentage of CD4+ and CD8+ T cells expressing the different types of cytokines was found after PBMC incubation with 10 Ilg/1l1 of MLBL (data not shown).
Effects of MLBL on expression of intracellular cytokines
The production of cytokines by in vitro MLBLstimulated immune CD4+ and CD8+ T cells was analyzed at the single cell level by simultaneous flow cytometric analysis of intracellular cytokines and surface antigen expression. PBMC were cultured for 24 hrs in the presence or absence of MLBL. At the end of incubation time, the frequencies of CD4+ or CD8+ T cells containing intracytoplasmic cytokines were determined analyzing, by two-color flow cytometric procedure, fixed and saponin-
Effect of MLBL on cytokine production at the single-cell level after re-stimulation
To evaluate the effects of MLBL on intracellular cytokine production after re-stimulation, PBMC were incubated for 120 hrs with 100 ug/rnl MLBL and then re-stimulated with a sub-optimal dose (10 ug/ml) ofMLBL. The frequencies ofCD4+ or CD8+ T lymphocytes singly expressing IL-2, IL-4, IL-IO and IFNy were determined by two-color flow cytometric procedure. The results showed ( Fig. 5 and  6 ) that the in vitro re-stimulation of PBMC with a sub-optimal dose of MLBL induced a marked increase versus unstimulated controls of the and clinical studies suggesting that MLBL can prime several immune responses against bacterial antigens, thus providing an effective barrier against invasion of pathogenic bacteria (5) (6) (7) (8) (9) (10) (11) (12) (13) (22) (23) (24) (25) .
In particular, the results demonstrated that MLBL treatment induced an increase in the percentage of either B lymphocytes or CD4+ and CD8+ T lymphocytes expressing CD25, a surface antigen corresponding to the a-chain ofthe IL-2 receptor (IL-* P< 0.05 **P<o.01 **P<O.001 (Student's t test). 2Ra) and considered to be an activation marker. This finding indicates that MLBL can modulate the IL-2-IL-2R signalling that is regarded as a pivotal mechanism in the development of immune response. In fact, the functional differentiation of lymphocyte subsets strictly depends on their activation by the Type I cytokine IL-2 (29) that exerts an essential role in the immune response by inducing lymphocyte PHENOTYPE a CD4+/IL2+ CD4+/IFN+ CD4+/IL4+ CD4+/IL 10+ expansion and effector cell differentiation.
The results also showed that MLBL can both modulate innate immunity and induce primary immune response by direct activation of the production of different cytokine patterns by immune competent cells. In fact, the treatment ofPBMC with MLBL increased both the frequency of CD4+ T cells producing IL2 and IL10 and the frequency of CD8+ T cells producing IL-2, IL-IO and IFNy. Moreover, cytokine detection by ELISA in culture supernatants showed an increase in the concentrations ofIL-2, IL-10, IL-12, and IFNy, in respect to control cultures.
All these cytokines play a major role in the defence mechanisms of the organism in response to bacterial infections. In particular, in the supernatants ofMLBL treated cells, the most represented cytokine is IL-12, a cytokine mainly produced by activated macrophages in response to many microbial products (30) that has a central role in the initiation of cellmediated immunity and in the linking of the responses of the innate resistance and adaptive immunity (31) . It is known, in fact, that IL-12 exerts a strong inducing effect on IFNy production by NK cells (32) , thus enhancing innate immunity responses and favouring the resistance to acute microbial infections. In addition, it is also an essential cytokine governing the differentiation of Type 1 responses mediated by T lymphocytes.
The other major Type 1 cytokine that we found both in culture supernatants and expressed in MLBLactivated CD8+ T cells was the IFNy. This cytokine is known to exert two key functions: i) macrophage activation and subsequent enhancement of their antimicrobial activity; ii) stimulation of the production of IgG antibodies against Fcy receptors and complement proteins that are the major antibodies involved in microbial opsonization and phagocytosis (33) (34) .
Finally, the data showed that the Type 2 cytokine IL-IO was largely produced by both CD4+ and CD8+ T cell subsets in MLBL-stimulated cultures. Also, this cytokine exerts an important antimicrobial activity, as it is known to activate B lymphocytes humoral responses and to be involved in the production of secretory IgA (sIgA) at the mucosal surfaces.
Taken together, the results on lymphocyte activation and cytokine production induced by treatment with MLBL show that, in addition to the activation of the innate immune responses through monocyte-induced release ofIL-12, MLBL can also activate the specific cellular and humoral immune response pathways.
In a series of experiments, PBMC were incubated with MLBL (100 ug/ml) for 5 days and then restimulated with a sub-optimal dose of MLBL (10 ug/ml) for 24 h. The results showed that MLBL induced the generation of antigen-specific effector T lymphocytes, as demonstrated by the increase, in both CD4+ and CD8+ T lymphocytes, of the rate of cytokine-producing cells after MLBL re-stimulation.
In particular, in re-stimulated PBMC cultures, CD4+ T cell subset showed an increased percentage of cells expressing Type 2 cytokines (IL-4 and IL-IO) in respect to both non-restimulated MLBL-treated cells and to MLBL-restimulated CD8+ T cells. This finding supports the hypothesis that MLBL restimulation could activate a secondary immune reaction recruiting a subset of effector CD4+ helper T cells secreting Type 2 (Th2) cytokines that may in turn activate B cell responses (17, 18, 20, 21, 35) , thus indirectly providing an efficient help for immunoglobulin synthesis allowing a protective humoral immunity (11, 16, 22) . As known, effector lymphocytes consist in antigen-experienced cells characterized by the capacity for production of very large amounts of multiple immunoregulatory cytokines upon re-stimulation with a low dose antigen (35) (36) (37) (38) . The enhanced secondary T cell response is due to the increased frequency of antigenspecific cells generated during the primary stimulation and to the cytokines present in the initial 5-days culture period that determine the developing cytokine profile of the effector populations (39) . All these cellular immune functions, in concert with antibody responses, form the basis for protective immunity against infections and diseases (40) (41) (42) . The finding that MLBL re-stimulation generates effector lymphocytes that have a rapid cellular and humoral immune response, represents an important mechanism of action that may explain the potential of MLBL to elicit protective immunity also in recurrent infections of the respiratory tract thus supporting its role as a vaccine.
In their whole, the present results suggest that the therapeutic effect of MLBL in acute and recurrent infections of the respiratory tract is related to its capacity to elicit innate and adaptive immune responses, both in humoral and cellular compartments, and that this effect may be either by direct activation of immune competent cells or mediated through the generation of immune effectors. These results also support the results of previous clinical investigations that linked the therapeutic efficacy of the sub-lingual delivery of lyophilized bacterial lysates both in acute (22) and recurrent (12, 13, 22) infections of the respiratory tract to the stimulation of the immune response.
In conclusion, mucosal immunization by bacterial lysates appears as a non-invasive vaccine approach that does not require the use of extraneous adjuvant and that, beside cost-effectiveness, has attractive practical and immunological features.
